Versant Vantage I, L.P.'s Net Worth
$49.8 Million
Who is Versant Vantage I, L.P.?
Versant Vantage I, L.P. has an estimated net worth of $49.8 Million. This is based on reported shares across multiple companies, which include Repare Therapeutics Inc., Monte Rosa Therapeutics, Inc., Oyster Point Pharma, Inc., Aligos Therapeutics, Inc., Pandion Therapeutics, Inc., Passage BIO, Inc., Black Diamond Therapeutics, Inc., RayzeBio, Inc., and Aprea Therapeutics, Inc..
SEC CIK
Versant Vantage I, L.P.'s CIK is 0001765253
Past Insider Trading and Trends
2020 was Versant Vantage I, L.P.'s most active year for acquiring shares with 75 total transactions. Versant Vantage I, L.P.'s most active month to acquire stocks was the month of May. 2020 was Versant Vantage I, L.P.'s most active year for disposing of shares, totalling 157 transactions. Versant Vantage I, L.P.'s most active month to dispose stocks was the month of October. 2020 saw Versant Vantage I, L.P. paying a total of $29,049,984.00 for 29,183,279 shares, this is the most they've acquired in one year. In 2022 Versant Vantage I, L.P. cashed out on 1,854,232 shares for a total of $9,188,775.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Monte Rosa Therapeutics, Inc. (GLUE) Snapshot price: $4.65
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +3,041.10% | 8.61M |
$19.00 |
—
| 8.9M |
Jun 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Oyster Point Pharma, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -3.66M |
—
|
—
|
0
|
Jan 3
| |||
Form 4
| -32.57% | -201.47K |
—
|
—
| 417.07K |
Scheduled
|
Jan 5
| ||
Form 4
| -24.57% | -201.47K |
—
|
—
| 618.55K |
Scheduled
|
Dec 21
| ||
Form 4
| -22.59% | -550.00K |
$14.86 | -$8,160,736.41 | 1.88M |
Scheduled
|
Oct 18
| ||
Form 4
| -19.05% | -322.36K |
—
|
—
| 1.37M |
May 12
| |||
Form 4
| -16.00% | -322.36K |
—
|
—
| 1.69M |
Mar 26
| |||
Form 4
| -12.69% | -325.00K |
—
|
—
| 2.24M |
Scheduled
|
Feb 17
| ||
Form 4
| +1,630.55% | 5.26M |
$16.00 |
—
| 5.58M |
Nov 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aligos Therapeutics, Inc. (ALGS) Snapshot price: $0.72
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.29M |
$15.00 |
—
| 3.29M |
Oct 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Pandion Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.75M |
—
|
—
| 3.75M |
Jul 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Passage BIO, Inc. (PASG) Snapshot price: $1.02
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 4.96M |
$18.00 |
—
| 4.96M |
Mar 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||